Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 12.06
(0.08%)
CNY 12.06
(0.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 651.98 Million CNY | -34.28% |
| 2022 | 1.09 Billion CNY | -23.85% |
| 2021 | 1.48 Billion CNY | 17.94% |
| 2020 | 1.24 Billion CNY | 33.85% |
| 2019 | 915.99 Million CNY | 20.04% |
| 2018 | 765.89 Million CNY | 24.99% |
| 2017 | 615.84 Million CNY | 28.5% |
| 2016 | 479.28 Million CNY | 30.6% |
| 2015 | 363.21 Million CNY | 9.19% |
| 2014 | 333.49 Million CNY | 21.67% |
| 2013 | 278.57 Million CNY | 28.91% |
| 2012 | 221.33 Million CNY | 41.24% |
| 2011 | 157.76 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 149.85 Million CNY | 101.71% |
| 2024 Q2 | 159.31 Million CNY | -22.85% |
| 2024 Q3 | 91.6 Million CNY | -44.68% |
| 2023 Q4 | 32.36 Million CNY | -79.64% |
| 2023 Q1 | 155.07 Million CNY | 12.59% |
| 2023 Q2 | 98.17 Million CNY | -36.69% |
| 2023 Q3 | 158.93 Million CNY | 61.88% |
| 2023 FY | - CNY | -34.28% |
| 2022 Q2 | 232.28 Million CNY | -17.71% |
| 2022 Q1 | 282.27 Million CNY | 37.73% |
| 2022 FY | - CNY | -23.85% |
| 2022 Q4 | 137.73 Million CNY | -40.22% |
| 2022 Q3 | 230.4 Million CNY | -0.81% |
| 2021 Q1 | 421.95 Million CNY | 53.11% |
| 2021 Q4 | 204.95 Million CNY | -41.85% |
| 2021 FY | - CNY | 17.94% |
| 2021 Q3 | 352.45 Million CNY | 18.13% |
| 2021 Q2 | 298.35 Million CNY | -29.29% |
| 2020 Q1 | 108.67 Million CNY | -27.91% |
| 2020 FY | - CNY | 33.85% |
| 2020 Q4 | 275.58 Million CNY | -26.57% |
| 2020 Q3 | 375.3 Million CNY | 17.69% |
| 2020 Q2 | 318.88 Million CNY | 193.44% |
| 2019 Q4 | 150.75 Million CNY | -35.34% |
| 2019 Q3 | 233.14 Million CNY | 1.3% |
| 2019 Q2 | 230.16 Million CNY | 21.48% |
| 2019 FY | - CNY | 20.04% |
| 2019 Q1 | 189.47 Million CNY | 29.42% |
| 2018 Q4 | 146.4 Million CNY | -18.08% |
| 2018 Q2 | 206.96 Million CNY | 42.69% |
| 2018 Q1 | 145.04 Million CNY | 37.56% |
| 2018 FY | - CNY | 24.99% |
| 2018 Q3 | 178.72 Million CNY | -13.65% |
| 2017 Q1 | 105.28 Million CNY | -4.71% |
| 2017 Q2 | 154.47 Million CNY | 46.72% |
| 2017 FY | - CNY | 28.5% |
| 2017 Q3 | 172.2 Million CNY | 11.47% |
| 2017 Q4 | 105.44 Million CNY | -38.77% |
| 2016 Q3 | 109.57 Million CNY | -27.25% |
| 2016 FY | - CNY | 30.6% |
| 2016 Q4 | 110.48 Million CNY | 0.84% |
| 2016 Q2 | 150.62 Million CNY | 107.35% |
| 2016 Q1 | 72.64 Million CNY | 0.54% |
| 2015 Q2 | 130.67 Million CNY | 68.76% |
| 2015 Q1 | 77.43 Million CNY | 25.47% |
| 2015 FY | - CNY | 9.19% |
| 2015 Q4 | 72.25 Million CNY | 7.9% |
| 2015 Q3 | 66.96 Million CNY | -48.76% |
| 2014 FY | - CNY | 21.67% |
| 2014 Q4 | 61.71 Million CNY | -11.59% |
| 2014 Q1 | 76.65 Million CNY | 0.0% |
| 2014 Q3 | 69.79 Million CNY | -41.56% |
| 2014 Q2 | 119.43 Million CNY | 55.82% |
| 2013 FY | - CNY | 28.91% |
| 2012 FY | - CNY | 41.24% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 64.951% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 77.095% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -125.726% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | 6.591% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | -37.256% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 24.111% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -176.169% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 8.796% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | -84.909% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 1204.886% |